Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia

Experimental Hematology

Volumn 31, Issue 11, 2003, Pages 1066-1072

  Barjesteh Van Waalwijk Van Doorn Khosrovani, Sahar ^a   Erpelinck, Claudia ^a   Löwenberg, Bob ^a   Delwel, Ruud ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GENE PRODUCT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD CELL; BONE MARROW; CONTROLLED STUDY; CORRELATION ANALYSIS; EVI1 LIKE GENE; GENE; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; MACROPHAGE; MAJOR CLINICAL STUDY; MDS1 EVI1 LIKE 1 GENE; MONOCYTE; NEUTROPHIL; NORTHERN BLOTTING; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; RISK ASSESSMENT; STEM CELL; T LYMPHOCYTE SUBPOPULATION;

EID: 0242352337     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2003.08.003     Document Type: Article

References (13)

1. Mochizuki N., Shimizu S., Nagasawa T., Tanaka H., Taniwaki M., Yokota J., et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood. 96:2000;3209-3214.
2. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., van Putten W.L., Valk P.J., van der Poel-van de Luytgaarde S., Hack R., et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 101:2003;837-845.
3. Fears S., Mathieu C., Zeleznik-Le N., Huang S., Rowley J.D., Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA. 93:1996;1642-1647.
4. Xinh P.T., Tri N.K., Nagao H., Nakazato H., Taketazu F., Fujisawa S., et al. Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5′ region of MEL1. Genes Chromosomes Cancer. 36:2003;313-317.
5. Boyum A. Separation of leukocytes from blood and bone marrow: introduction. Scand J Clin Lab Invest Suppl. 97:1968;7.
6. Delwel R., Touw I., Bot F., Lowenberg B. Fucose binding lectin for characterizing acute myeloid leukemia progenitor cells. Blood. 68:1986;41-45.
7. Rombouts W.J., Lowenberg B., van Putten W.L., Ploemacher R.E. Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene. Leukemia. 15:2001;1046-1053.
8. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 103:1985;620-625.
9. Delwel R., van Buitenen C., Salem M., Bot F., Gillis S., Kaushansky K., et al. Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. Blood. 74:1989;586-593.
10. Barjesteh Van Waalwijk Van Doorn-Khosrovani S., Erpelinck C., Meijer J., Van Oosterhoud S., Van Putten W.L., Valk P.J., et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J. 4:2003;31-40.
11. Morishita K., Nishikata I. A novel EVI1 gene family, MEL1 lacking a PR domain (MEL2) is mainly expressed in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. [abstract] Blood. 100:2002;11. Abstract 2115.
12. Morishita K., Parganas E., William C.L., Whittaker M.H., Drabkin H., Oval J., et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA. 89:1992;3937-3941.
13. Preudhomme C., Sagot C., Boissel N., Cayuela J.M., Tigaud I., de Botton S., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 100:2002;2717-2723.